As of June 30, 2025, the Company had cash and investments of $254.5 million. The cash balance as of June 30, 2025 does not include the net proceeds of $81.1 million raised in the recently completed public offering in July 2025. With the recent net proceeds in addition to our cash and investments, we expect to fund operations to mid-2027.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVBP:
- ArriVent BioPharma, Inc. (AVBP) Q2 Earnings Cheat Sheet
- ArriVent BioPharma Positioned for Success: Buy Rating on Strong Phase 3 Prospects and Financial Health
- ArriVent Biopharma management to meet with Oppenheimer
- ArriVent BioPharma’s Promising Clinical Trials and Strategic Plans Drive Buy Rating with $40 Price Target
- Buy Rating for ArriVent BioPharma: Promising Potential of Lead Candidate and Solid Financial Position